UNCY UNICYCIVE THERAPEUTICS INC

EQS-News: Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden

EQS-News: Unicycive Therapeautics, Inc.
Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden

08.11.2022 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Anne Marie Fields - Stern Investor Relations

Company Website


News Source: News Direct

08.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Unicycive Therapeautics, Inc.
United States
ISIN: US90466Y1038
EQS News ID: 1482189

 
End of News EQS News Service

1482189  08.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1482189&application_name=news&site_id=research_pool
EN
08/11/2022

Underlying

UNCYUNICYCIVE THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNICYCIVE THERAPEUTICS INC

 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim...

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET. A link to the live and archived webcast may be accessed on th...

February 4, 2026 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthan...

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the ...

January 29, 2026 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbon...

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmissi...

January 29, 2026 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics Announces Resubmission of New Drug Application ...

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) New PDUFA date expected in 1H 2026 within 30 days of NDA resubmission LOS ALTOS, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oxylanthanum carbonate (OLC), the Company’s investigational...

December 29, 2025 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics to Participate in Upcoming Investor Events in D...

Unicycive Therapeutics to Participate in Upcoming Investor Events in December LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in two investor events in December. Event: Piper Sandler 37th Annual Healthcare ConferenceType: Fireside chatDate/Time: Wednesday, December 3, 2025, at 10:00 a.m. ET Event: Noble Capital Markets Virtual Prese...

November 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch